poisar

Stocks · News reference

Rep. Pete Sessions Has Sold Up to $100K Worth Of AbbVie Stock: Here’s What You Should Know

Benzinga Insights

An official report on September 18, 2026 reveals Representative Pete Sessions's recent sale of AbbVie (NYSE:ABBV) stock, valued between $30,002 and $100,000. The transaction took place on September 14, 2026, as per

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABBVARCCGOOGL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

    The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.

    JNJMLTXABBVAMGNTAK
  2. Benzinga Newsdesk

    AbbVie Enters Multi-Year Collaboration With Iambic To Accelerate Discovery And Development Of Small Molecule Therapies Across Immunology, Neuroscience And Oncology; Iambic To Receive Upfront Payment And Is Eligible For Milestone Payments And Tiered Royalties

    The companies will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug candidates."We are excited about the purpose-built AI capabilities Iambic is bringing to

    ABBV
  3. Sara Appino

    AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

    AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.

    ABBVBMYCELGRMCKCAH
  4. Researchandmarkets.Com

    Fitness Tracker Market Set for Growth Through 2033 as AI-Powered Wearables and Rising Health Awareness Fuel New Business Opportunities

    The global fitness tracker market is projected to grow from USD 71.2 billion in 2026 to USD 91.6 billion by 2033, with a CAGR of 3.70%. Growth is driven by AI-enabled wearables, rising health awareness, integration with healthcare platforms, and expanding adoption in emerging markets. Key opportunities exist in affordable devices, multifunctional wearables, and partnerships with healthcare and wellness providers.

    AAPLGOOGGOOGLGOOGMGOOGN
  6. Globe Newswire

    Glass Launches AI-Powered G-Commerce Supplier Experience, Giving Businesses a New Way to Sell to Governments

    Glass, a Silicon Valley GovTech company, launched an AI-powered G-Commerce Supplier Experience platform that enables businesses to sell products and services to government agencies through a centralized marketplace. The platform features AI-powered verification, a supplier API for catalog integration, order management tools, and support resources to help suppliers navigate government procurement.

    GOOGGOOGLGOOGMGOOGN